Healthcare Global Enterprises Limited, India's largest dedicated cancer hospital network, announced its financial results for the quarter and nine months ended December 31, 2025. The company demonstrated steady performance with revenue growth and margin expansion despite seasonal challenges in the healthcare industry.

Financial Performance Overview

The company's consolidated financial results showed robust growth across key metrics for both the quarter and nine-month periods:

Management Commentary on Results

Dr. Manish Mattoo, CEO of Healthcare Global Enterprises Ltd., highlighted that the Q3 performance reflects steady execution across the network despite seasonal softness in the healthcare industry. He noted that revenues of ₹6,331 Mn were supported by balanced performance across regional clusters, demonstrating resilient demand for high-quality oncology care across medical, radiation, and surgical oncology modalities.

The quarter demonstrated the scalability of the company's model, with adjusted EBITDA margins expanding due to operating leverage. Dr. Mattoo emphasized that HCG's focused single-specialty model, anchored in integrated care delivery and tumour-board-led clinical decision-making, continues to differentiate the company in a competitive environment, supporting strong referral flows and patient trust.

Strategic Focus and Clinical Excellence

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, outlined the company's guiding principle of delivering the right treatment the first time with a focus on patient outcomes. As a single-specialty oncology institution with a nationwide network, HCG has built a deeply integrated care model that combines:

• Advanced diagnostics and genomics
• Multi-omics and organ-specific pathology
• Tumour-board-led decision-making
• Emerging therapies such as CAR-T

The company's commitment to clinical research is reflected in HCG clinicians contributing to one of the largest bodies of oncology research from India, with regular representation at leading international forums worldwide.

Organizational Strengthening

The company has completed senior leadership augmentation across key functions including marketing, domestic sales, and international business to support the next phase of growth. This strengthening of leadership bandwidth positions HCG for continued expansion across both metro and non-metro markets in India.

About Healthcare Global Enterprises

Headquartered in Bengaluru, Healthcare Global Enterprises Ltd. operates India's largest dedicated cancer hospital network. Through its network of 25 hospitals across India and Africa, HCG provides advanced cancer care with comprehensive cancer centers offering expertise and technologies for effective diagnosis and treatment under one roof. The company also operates fertility centers under the "Milann" brand.

Healthcare Global Enterprises Limited's Board of Directors has approved the introduction and adoption of a new employee stock option scheme during their meeting held on February 05, 2026. The HCG Employee Stock Option Scheme 2026 (HCG ESOS 2026) was approved based on recommendations from the company's Nomination and Remuneration Committee.

ESOP Scheme Details

The newly approved employee stock option scheme encompasses significant parameters for employee benefits:

Vesting and Exercise Framework

The scheme will be administered by the Nomination and Remuneration Committee, with specific guidelines for vesting periods:

• Minimum vesting period: 1 year from grant date
• Maximum vesting period: 7 years from grant date
• Exercise timeline: As per ESOP scheme terms
• Committee oversight: NRC will determine specific vesting schedules

Pricing Structure

The exercise price structure follows a tiered approach based on grant timing. For options granted prior to June 30, 2026, the exercise price is fixed at INR 495. For options granted after June 30, 2026, the Nomination and Remuneration Committee will determine the price, ensuring it remains not below INR 495.

Regulatory Compliance and Approval Process

The HCG ESOS 2026 aligns with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The board meeting, which commenced at 12 noon and concluded at 7.35 p.m. IST, addressed the regulatory requirements under Regulation 30 of SEBI Listing Regulations.

Key compliance aspects:

• Subject to shareholders' approval
• Detailed explanatory statement for shareholders' meeting
• Full regulatory disclosure requirements met
• SEBI circular compliance maintained

Current Status

As this represents a new employee stock option plan, no options have been vested, exercised, or lapsed to date. The scheme implementation awaits shareholder approval, after which the company can proceed with grant allocations to eligible employees. The board's decision reflects the company's commitment to employee retention and incentivization through equity participation.